GPI S.p.A (GPI) Fair Value & Analysis
Healthcare · IT · Market cap €422M
Fair value as of: Jun 24, 2026
From 16 valuation models · updated 5 days ago
Share price −5.9% over the past month.
Price vs Fair Value (12 months)
12‑month range €11.22 – €19.22 · fair‑value band €9.25 – €17.51 · the €15.14 price screens above the €12.33 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GPI S.p.A (GPI) currently trades at €15.14, while our model-based Fair Value estimate is €12.33 — implying the stock looks roughly 18.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, GPI S.p.A generated revenue of €546M at a net margin of 3.0%. Revenue grew 5.2% year over year. It earns a return on equity of 5.0%. Net debt stands at €305M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
GPI S.p.A. provides social-healthcare and information technology hi-tech services in Italy and internationally. It offers population health management; healthcare administration and accounting, human resources management, management systems, and payment and storage solutions; hospital information access systems, clinical, diagnostic systems, and repository and integration middleware solutions; and social-health and welfare system, territorial social-health system, continuity of care, as well as prevention, public health, and veterinary medicine solutions. The company also provides LIS, pathological anatomy, and RIS PACS imaging diagnostic information system; transfusion systems and analysis laboratory transfusion information systems; virtual care, CUP and multichannel BPO services, outpatient clinics and clinics, and 3D prosthetics technologies and services; and robot for pharmacy and automated hospital pharmacy. In addition, it offers management systems for public administration, l…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GPI S.p.A reported revenue of €530M in FY2025 versus €324M in FY2021, a compound +13.1%/yr. Reported net income was €16.2M in FY2025, compounding +10.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GPI S.p.A (GPI) undervalued?
What is the fair value of GPI?
What is the quality score of GPI?
What is the revenue of GPI S.p.A (GPI)?
What is the net profit margin of GPI?
Does GPI S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.